Quantum magnetometry for brain and heart imaging (OPM-MEG, MCG): Junction Brief – November 2026

Acentric Research is produced with AI tools under human review. The authors are not financial professionals, and nothing here is investment advice or a recommendation to buy or sell any security. AI analysis can be wrong; check every claim against its cited source.

This Brief is an initial scan, not a full investigation. The method and scores behind it are in Biotechnology × Quantum in the Landscape Report.

Overview

Nerve cells and heart muscle make tiny magnetic fields as they fire. [1][2] Magnetoencephalography (MEG) measures the brain's field; magnetocardiography (MCG) measures the heart's. Conventional MEG machines use superconducting sensors, called SQUIDs, cooled to very low temperatures, which NIH's page describes as prohibitively expensive to acquire and maintain and difficult to connect comfortably to the head. [3] A newer sensor, the optically pumped magnetometer (OPM), reads magnetic fields and, per NIH's page, operates at room temperature. [3][2]

What stands out is that this has reached a cleared medical device on the heart side and research sales on the brain side. FDA's 510(k) database records a clearance of Genetesis's CardioFlux heart-imaging system in March 2019, and the company says it uses OPMs. [4][2] The dated sources opened run from 2019 to 2026, apart from two earlier FDA records (2004 and 2017) returned by a device-name search; the FDA clearance and the main reviews are from 2019 to 2023, and later developments in heart imaging were not searched.

Current state

What the technology does. A 2022 review of OPM-MEG says the sensors promise better sensitivity and spatial resolution, fit to any head size from babies to adults, tolerance of movement during scanning, and no need for cryogenics (abstract read; full text not read). [1] The UK national quantum technologies programme describes the first wearable MEG system, built by researchers in its Sensors and Timing hub, which sits on the scalp and lets people move during scanning. [5]

Brain imaging. QuSpin, a Colorado company, describes a wearable OPM-MEG system. The NIH page says these scanners are being deployed, in collaboration with Cerca Magnetics, at the Hospital for Sick Children in Toronto, Princeton University, the University of Zurich and Boys Town National Research Hospital. The same page says QuSpin began applying for small-business research grants in 2012 and that the system is "poised to enter the medical device market". [3] Cerca Magnetics, a University of Nottingham spinout, says it has sold 19 systems to neuroscience centres in 12 countries and is progressing through clinical approval pathways in the UK and the United States. [6][5] These are company statements. A search of FDA's 510(k) database by device name returned no OPM brain scanner; that does not prove none exists. [4]

What companies and programmes say about patients. Cerca's release says its wearable sensors let patients move naturally during scans and says it allowed brain imaging on infants for the first time, and the NIH page says earlier tools such as functional magnetic resonance imaging and SQUIDs are often uncomfortable and impractical, particularly for infants and children. [6][3] The UK programme says the system has been installed at Young Epilepsy for children with epilepsy, and gives the Hub's claim that signal detection improves five-fold with the sensor placed on the scalp. [5]

Heart imaging. Genetesis announced in March 2019 that FDA had cleared its CardioFlux magnetocardiograph with a cloud analysis service, for chest-pain triage; the company says OPMs remove the need for liquid helium cooling. [2] The FDA record shows a decision of "Substantially Equivalent" on 15 March 2019 for "CardioFlux with Faraday Analytical Cloud", and does not itself state the sensor type; a search by device name also returned a 2004 magnetocardiograph clearance (K033488, CMI Cardiomag Imaging) and a 2017 one (K170154, Creavo Medical Technologies), so the 2019 system was not the first magnetocardiograph cleared. [4]

How far it has come. One heart system that its maker says uses OPMs was cleared in the United States in 2019; its current marketing status was not checked, and the sensor type in the 2017 clearance was not checked. OPM brain scanners are sold for research. A review abstract calls OPM-MEG an emerging technique, and the 2023 review of quantum sensors names optically pumped magnetometers as one of two focus platforms, with brain imaging as one of its four case studies. [4][6][1][7] Diamond sensors, a different magnetic-field technology, are covered separately; the diamond approach is covered in its own Junction Brief.

Opportunities

Cerca's maker says a Series A of £3.8 million will support clinical approval, manufacturing scale-up and expansion, and that the technology is applied to epilepsy, multiple sclerosis and dementia research. [6] The UK programme says wearable MEG avoids the high installation and running costs of a conventional system. [5] This Brief did not search ClinicalTrials.gov or the literature for patient studies of OPM brain scanners, so it does not say whether such evidence exists.

Challenges

  • Regulation. No FDA clearance for an OPM brain scanner was found in a name search of the 510(k) database. The Cerca release says approval is in progress. [4][6]
  • Capital and scale-up. Cerca's release says the Series A will support clinical approval and manufacturing scale-up; the sources opened give no cost figures for the sensors. [6]

Data sources

  • FDA 510(k) database, for clearances of MEG and MCG systems; searched by device name only here. [8][9]
  • NIH RePORTER, for grants such as small-business awards. [10]
  • ClinicalTrials.gov, for studies using OPM scanners. [11]
  • Europe PMC, for the research literature. [12]
  • No source of sales data for these systems was found beyond company statements.

Changelog

  • 2026-11-18: First published.

Sources

  1. Matthew J. Brookes and others, "Magnetoencephalography with optically pumped magnetometers (OPM-MEG): the next generation of functional neuroimaging", Trends in Neurosciences, 2022, abstract (Europe PMC record, PMID 35779970; the full text was not read). ebi.ac.uk (accessed 2026-11-18)
  2. MedTech Innovator, "Genetesis CardioFlux platform receives FDA 510(k) clearance", 2019-03-22 (company announcement reproduced by an accelerator). medtechinnovator.org (accessed 2026-11-18)
  3. NIH Small Business Education and Entrepreneurial Development (SEED), "QuSpin Technology Takes Brain Scanning to the Next Level", success story dated 2025-02-27 (agency page relaying company statements). seed.nih.gov (accessed 2026-11-18)
  4. openFDA 510(k) database, record K182571, "CardioFlux with Faraday Analytical Cloud", Genetesis, Inc., decision date 2019-03-15, "Substantially Equivalent" (agency data, queried through the API; the device-name searches "magnetoencephalograph*" and "MEG" returned no optically pumped magnetometer system, which is not proof of absence). api.fda.gov (accessed 2026-11-18)
  5. UK National Quantum Technologies Programme, "Four ways quantum technologies are advancing the future of healthcare", 2022-05-24 (programme statement). uknqt.ukri.org (accessed 2026-11-18)
  6. The Quantum Insider, "Cerca Magnetics Secures £3.8M Series A Funding to Scale Quantum Brain Scanner", 2026-04-21 (trade press reproducing a company press release; the sales, clinical-approval and growth statements are the company's). thequantuminsider.com (accessed 2026-11-18)
  7. Nabeel Aslam and others, "Quantum sensors for biomedical applications", Nature Reviews Physics, 2023, abstract (Europe PMC record, PMID 36776813; the full text was not read). ebi.ac.uk (accessed 2026-11-18)
  8. FDA 510(k), De Novo and PMA databases. accessdata.fda.gov (listed as a data source; the 510(k) record cited was read through openFDA)
  9. openFDA, device 510(k) data. open.fda.gov (queried by device name for this Brief, 2026-11-18)
  10. NIH RePORTER, project search. reporter.nih.gov (listed as a data source, not opened for this Brief)
  11. ClinicalTrials.gov, study search. clinicaltrials.gov (listed as a data source; not searched for this Brief)
  12. Europe PMC REST API. ebi.ac.uk (listed as a data source; review abstracts were read through it for other claims in this Brief, 2026-11-18; not searched for this Junction)